Business Context and Reporting Period
This Form 8-K filing by Galectin Therapeutics Inc. covers events occurring on March 22, 2012. The company, incorporated in Nevada, is a biopharmaceutical entity headquartered in Newton, Massachusetts. The report details a capital raise, a reverse stock split, and a change in stock listing venue.
Key Financial Metrics and Capital Structure
- Capital Raise: The Company entered into an underwriting agreement to sell 1,159,445 Units at a public offering price of $9.00 per Unit.
- Unit Composition: Each Unit consists of two shares of Common Stock and one Warrant to purchase one share of Common Stock.
- Over-Allotment: Underwriters were granted a 45-day option to purchase up to an additional 173,916 Units.
- Warrant Terms: Initial exercise price of $5.63 per share; exercisable upon separation of Units; expiration date of March 28, 2017.
- Reverse Stock Split: A one-for-six (1:6) reverse stock split was effected, effective March 22, 2012, at 4:01 PM EDT.
- Liquidity and Listing: The filing does not provide specific cash flow, debt, or liquidity metrics. The Company's Common Stock ceased trading on the OTC Bulletin Board and commenced trading on The NASDAQ Capital Market under the symbol "GALT" effective March 23, 2012.
Material Changes Versus Prior Period
- Listing Status: Transitioned from the OTC Bulletin Board to The NASDAQ Capital Market.
- Share Structure: Implemented a 1:6 reverse stock split, adjusting the number of authorized and outstanding shares.
- Security Adjustments: Conversion prices of outstanding convertible preferred stock and exercise prices of outstanding warrants were adjusted to reflect the reverse stock split.
- Trading Symbols: New symbols established: "GALT" (Common Stock), "GALTU" (Units), and "GALTW" (Warrants).
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future performance, or specific risk factors beyond the standard closing conditions of the offering. The offering is expected to close on or about March 28, 2012, subject to customary closing conditions. The Units may not be separated into underlying shares and warrants until the earlier of the exercise of the over-allotment option or 45 days from the final prospectus supplement.
Key Facts for Investor Verification
- Verify the final closing date of the offering and the total proceeds raised, including any exercise of the over-allotment option.
- Confirm the post-split share count and the adjusted exercise prices of all outstanding equity instruments.
- Monitor the trading status of the Common Stock, Units, and Warrants on The NASDAQ Capital Market.
- Review the full Underwriting Agreement and Warrant Agreement (Exhibits 1.1, 4.1, and 4.2) for detailed terms not summarized in this report.